LEO Pharma, which the release describes as a global leader in medical dermatology, serves close to 100 million patients in more than 70 countries annually.The post Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m appeared first on PE Hub.
Source: PE Hub · Summarized by HeadlinesBriefing